Clinical

Joel W. Neal, MD, PhD, associate professor, Division of Oncology, Stanford Cancer Institute, is lead investigator on the COSMIC-021 trial, which is investigating cabozantinib plus atezolizumab vs cabozantinib alone in patients with advanced non–small cell lung cancer (NSCLC) as a possible second-line treatment beyond chemotherapy.

Thanos Zomas, MD, global medical lead, Lymphoma and Leukemia, and global medical lead, Adcetris Program, at Takeda Oncology discusses updated results from the ECHELON-1 study.

Levels of the 2 markers appeared to indicate both the presence of SLE and disease activity levels.

Preventing graft-versus-host disease (GVHD) after allogeneic stem cell transplant is a key aspect of patient management, but current cyclosporine concentration guidelines may not be sufficient, according to a recent study.

The researchers underscored the importance of the patient voice in the field, as some aspects of treatment can only be assessed through the patient.

Data presented at ASCO show that after 6 years, patients with advanced Hodgkin lymphoma who were treated with a combination of brentuximab vedotin and chemotherapy had a sharply reduced risk of death and a reduced risk of a secondary cancer.

Little data exist on the effectiveness of dupilumab in Black and Hispanic children, even though severe asthma disproportionately affects these populations.

Undifferentiated connective tissue disease (UCTD) is challenging to define but is a distinct clinical entity from connective tissue diseases (CTD).

Sacubitril/valsartan reduced mean pulmonary artery pressure (mPAP) and improved lung congestion, functional capacity, and quality of life in a subset of patients with heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF-PH) using a remote monitoring platform.

The label expansion means risdiplam is approved for spinal muscular atrophy for all ages.

Panelists share their final insights on improving the trajectory for women’s health care.

This study investigated the 1-year incidence of extrapyramidal symptoms (EPS), as well as the incremental economic burden, in patients with schizophrenia initiating atypical antipsychotics.

This expert panel considers an increasing collaborative effort between payers, patients, and providers for patient-centered care.

Findings from the phase 3 SHINE trial could make ibrutinib the standard treatment option for older patients with mantle cell lymphoma (MCL), who often cannot tolerate chemotherapy or transplant strategies, according to study authors.

Forty-two percent of patients in the cohort had an adverse pregnancy outcome.

Encouraging outcomes in recent studies have the authors of a recent review calling for more research on the effect of cannabinoids on sleep disorders.

The analysis suggests the marker could be used to screen patients for potential immunotherapy.

Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar SB5 and a high-concentration version.

A payer discusses medical exceptions processes and triggers for a class review for drugs in women’s health, along with wraparound programs for uterine fibroids and endometriosis.

A medical professional explains the many facets of the prior authorizations process for drugs in women’s health.

Ryan Haumschild, PharmD, MBA, MS, provides background on the Affordable Care Act (ACA) within the scope of women’s health, including specific mandates on contraceptives.

This new study, from Taiwan, investigated how menopause affects ventricular structure and function and its possible impact on heart failure among women.

Tisagenlecleucel (tisa-cel) was approved to treat adults with relapsed or refractory (R/R) follicular lymphoma. This is the third indication for the therapy since it became the first FDA-approved chimeric antigen receptor T-cell therapy in 2017.

This new study from Canada compared outcomes in patients living with type 1 diabetes who used 2 closed-loop insulin delivery systems: a fully artificial pancreas that did not require meal input and a hybrid artificial pancreas that required carbohydrate counting.